Recent Updates — CELZ

On September 24, 2026, Creative Medical Technology Holdings, Inc. entered into a Stock Purchase Agreement with Creative Acquisition Corp. to acquire 12,000,000 additional shares of BioDefense, Inc., bringing its total ownership to 16,000,000 shares, or 80% of BioDefense's outstanding common stock. The transaction consideration consisted of $200,000 in cash and 1,000,000 shares of Creative Medical Technology Holdings' common stock issued via private placement. Timothy Warbington, the Company's President and CEO, also serves as Chairman and CEO of Creative Acquisition Corp., which retains a 20% stake in BioDefense. This acquisition establishes majority control over BioDefense, expanding the Company's portfolio into medical technology solutions.

On August 28, 2026, Creative Medical Technology Holdings, Inc. stockholders approved an amendment to increase authorized common shares from 25 million to 100 million and the full exercise of investor warrants for 5,580,680 shares. The share increase proposal passed with 2,488,537 votes in favor against 595,527, while warrant approval received 678,541 votes for and 344,460 against. Creative Medical Technology Holdings operates in the medical technology sector, focusing on minimally invasive treatments for chronic pain.

Creative Medical Technology Holdings, Inc. entered into inducement letters with warrant holders to reduce the exercise price of 2,790,340 existing warrants from $2.86 to $1.60 per share, generating approximately $4.5 million in gross proceeds. In exchange, the company issued 5,580,680 new inducement warrants at an exercise price of $1.60 per share. The company plans to use the net proceeds for working capital and general corporate purposes. Creative Medical Technology is a medical technology company providing medical devices and services.